On Ghent's Founder-Friendly Spin-Out Playbook, and Why Lean Beats Big in AgTech- Chiara Guidi, B-COS

Episode 117: B-COS: Chiara Guidi on Ghent's Founder-Friendly Spin-Out Playbook, Plant Vaccines Over Pesticides, and Why Lean Beats Big in AgTech

In this episode, I speak with Dr. Chiara Guidi, Co-Founder & CEO of B-COS — a University of Ghent spin-off, incubated at Biotope by VIB, that is building "plant vaccines": carbohydrate bioactives (chito-oligosaccharides) produced by precision fermentation that switch on a crop's own defense system, making it more resilient and cutting the need for chemical pesticides. A year out of academia, Chiara and her team have raised €1M combining VC and grant funding. She gives an unusually candid look at what it takes to commercialize 15 years of university research: how B-COS became the very first company through Ghent's new "Fast Lane" spin-out program — a standardized, founder-friendly deal (low equity, low royalties, a worldwide exclusive perpetual license) that let them incorporate in a month instead of a year — and why a brand-new deal structure that no investor had seen before became one of the trickiest parts of the raise. We dig into how she turned public research into a de-risked asset investors love, how she built commercial traction at pre-seed through 100+ customer conversations, the two-track product strategy (long-horizon crop protection plus faster-to-market biostimulants), the reality of Belgium's grant ecosystem, and a refreshingly disciplined, "lean-and-mean" philosophy on valuation and survival.

🎧 Listen to the full episode to hear why a spin-out license can hand investors 15 years of de-risked science essentially for free, how B-COS answered the "there's nothing here yet" objection at pre-seed, why you often need funding in hand before you can win a VLAIO grant, how Chiara benchmarks valuation in a market with only five or six possible acquirers, and her answer to the question every deep-tech founder dreads: why won't the giants just crush you?

Key Facts: B-COS

• Chiara Guidi (Co-Founder & CEO): https://www.linkedin.com/in/chiara-guidi-
• Website: b-cos.eu
• Headquarters: Belgium
• What They Do: "Plant vaccines" for sustainable crop protection. B-COS uses precision fermentation to produce carbohydrate bioactives (chito-oligosaccharides) that activate a crop's natural defense system — improving resilience against fungal disease, nematodes, and drought stress, and reducing chemical pesticide use. Initial focus crop: 
• Funding: €1M pre-seed (VC + grants), backed by Agri Investment Fund (AIF) and VP Capital, with support from Biotope by VIB, a VLAIO research grant, and EIT (European Institute of Innovation & Technology).

Blurb

B-COS is built on an elegant idea: instead of spraying crops with chemicals to kill what attacks them, teach the plant to defend itself. Using precision fermentation to brew carbohydrate bioactives — chito-oligosaccharides that act like a vaccine for plants — B-COS switches on a crop's own immune response, building resilience to fungal disease, nematodes, and drought while cutting reliance on synthetic pesticides. Spun out of fifteen years of research at Ghent University and incubated at Biotope by VIB, it is a platform with reach well beyond its first focus crop.